B7-H3 in Cancer - Beyond Immune Regulation

Karine Flem-Karlsen; Øystein Fodstad; Ming Tan; Caroline E Nunes-Xavier

doi:10.1016/j.trecan.2018.03.010

B7-H3 in Cancer - Beyond Immune Regulation

Trends Cancer. 2018 Jun;4(6):401-404. doi: 10.1016/j.trecan.2018.03.010. Epub 2018 Apr 20.

Authors

Karine Flem-Karlsen¹, Øystein Fodstad¹, Ming Tan², Caroline E Nunes-Xavier³

Affiliations

¹ Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
² Center for Cell Death and Metabolism Research, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
³ Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. Electronic address: carnun@rr-research.no.

PMID: 29860983
DOI: 10.1016/j.trecan.2018.03.010

Abstract

B7-H3, a member of the B7 family of immunoregulatory proteins, is overexpressed in cancer and promotes tumor growth, metastasis, and drug resistance. We discuss here the involvement of B7-H3 in cancer that goes beyond its immune regulatory function, and discuss the potential of B7-H3 as a biomarker and therapeutic target.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

B7 Antigens / immunology*
Cell Transformation, Neoplastic / immunology*
Humans
Immunotherapy*
Neoplasms / immunology*
Neoplasms / therapy*

Substances

B7 Antigens
CD276 protein, human